Dermatol. praxi. 2018;12(1):36-39 | DOI: 10.36290/der.2018.034

Omalizumab in the long-term management of severe chronic spontaneous urticaria – clinical experience

MUDr. Olga Filipovská

Kožní oddělení, Masarykova nemocnice v Ústí nad Labem, o. z., Krajská zdravotní, a. s.

17 patients with severe chronic spontaneous urticaria (CSU) with UAS7 score ≥ 28, not responding to an increased dose of H1-antihistamines,have been treated with omalizumab in the department of Dermatology of Masaryk Hospital Ústí nad Labem in2015–2017. Most of the patients for the severity of their disease have also been treated with corticosteroids for the long term,some patients have received cyclosporin A, methotrexate, montelukast, azathioprine. Treatment with omalizumab was successfulwith all the patients, 40% of patients achieving complete remission at 12 weeks of therapy. With all the patients, after initiation oftreatment with omalizumab, the dose of H1 antihistamines could be reduced to standard and the corticosteroids, montelukastand immunosuppressants therapy was discontinued. After termination of the omalizumab therapy, the patient relapsed with thedisease, after re-initiation of the treatment the response level was similar to the previous cycles.

Keywords: omalizumab, monoclonal anti- IgE antibody, chronic spontaneous urticaria (CSU)

Received: January 22, 2018; Accepted: March 5, 2018; Prepublished online: March 5, 2018; Published: March 22, 2018  Show citation